Skip to main content
TipRanks
Go Ultimate75% OFF

Ryman Healthcare (RYM) AI Stock Analysis

4 Followers
NZ:RYM

Ryman Healthcare

(NZX:RYM)

Select Model
Rating:56Neutral
Price Target:NZD 2.00â–²(6.38% Upside)
Action:initiatedcoverage
Date:10/05/26

The score is supported primarily by improving cash generation and constructive earnings-call guidance around cost-out, balance-sheet strengthening, and disciplined development spending. Offsetting this are weak and volatile profitability (recent large losses) and bearish technical signals with the stock trading below major moving averages; valuation is also constrained by loss-making results (negative P/E) and no provided dividend yield.

Positive Factors
Strong cash generationThe return to positive free cash flow provides internally generated funding for debt reduction, essential investment and future distributions. Because it was supported by stronger sales, lower development spending and land divestments, it marks meaningful progress in financial resilience rather than merely accounting improvement.
Negative Factors
Persistent profitability weaknessRevenue growth has not yet translated into dependable profits, leaving returns on capital weak and making future performance more sensitive to execution. Sustained operating losses can constrain reinvestment and shareholder distributions, even while reported cash flow remains positive.

Ryman Healthcare (RYM) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%NZ:RYM-34.93%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 992.80M
Dividend Yield
―
Average Volume (3M)
1.93M
Price to Earnings (P/E)
-11.2
Beta (1Y)
1.74
Revenue Growth
11.86%
EPS Growth
72.99%
Country
NZ
Employees
7,800
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Ryman Healthcare Business Overview & Revenue Model

Company Description

Ryman Healthcare Limited, established in Christchurch, New Zealand, in 1984, specializes in the development, ownership, and management of all-encompassing retirement communities for seniors. Operating across both New Zealand and Australia, the compan...

How the Company Makes Money

Ryman makes money primarily through its integrated retirement village and aged-care model. A core revenue stream comes from selling occupation rights to residents (commonly structured as an occupation right agreement rather than a freehold sale), whe...

Ryman Healthcare Earnings Call Summary

Earnings Call Date:May 25, 2026(Q4-2026)|% Change Since:-14.16%|Next Earnings Date:Nov 25, 2026
Earnings Call SentimentPositive

The call reported clear operational progress: doubled operating EBITDAF, strong aged-care performance (EBITDAF per bed +31%), significant cost savings ($57m), positive free cash flow of $188m, reduced development exposure and a strengthened balance sheet (refinancing, lower interest costs). Management acknowledges remaining challenges — resale stock and margins, timing of DMF cash benefits, one-off transformation costs, FX effects and regional market competitiveness — and provided targets and actions (sales/marketing investment, land divestments, product changes, and a $150m CFEO improvement target to FY'29). Overall the positives — particularly cash generation, cost-out, and aged care momentum — materially outweigh the current lowlights, supporting a constructive outlook while risks from market conditions and timing remain.

Positive Updates

Positive Free Cash Flow
Delivered positive free cash flow of $188 million in FY'26 — the first positive free cash flow in over a decade — driven by robust new sales, moderating development spend and land-bank divestments.

Negative Updates

Resale Margin Moderation and Bought-Back Stock
Resale margin moderated (20.3% in H1 to 19.9% FY'26) amid lower house price inflation; net resale cash flow softer due to a $53 million increase in bought-back stock and lower resale margins, increasing short-term cash drag.

Company Guidance

Ryman’s guidance emphasizes cash generation, disciplined development and growing care earnings: management is targeting to lift retirement‑living resales to match turnover by end FY'27, expects lower FY'27 build and CapEx with only 2 active construction sites and ~50% of FY'27 development CapEx already locked (committed cost‑to‑go on main buildings ~$190m), and is prioritising care where EBITDAF per bed is targeted at $25,000–$30,000 by FY'29 (H2 FY'26 was $20,200/bed; FY'26 country run‑rates were NZD15,000 in NZ and ~NZD32,000 in AU). Medium‑term financial targets remain a $150m improvement in sustainable CFEO by FY'29 (already $47m achieved in year one) and a $500m cash‑release program (FY'26 delivered $169m, with a further $75m locked in and $147m of land sales contracted — $72m cash received to date; management has raised the land‑divestment ambition to ~ $250m), plus targets to reduce normalized non‑village costs to < $100m by FY'29. Balance‑sheet guidance: FY'26 free cash flow was $188m, net debt $1.57bn with $675m facility headroom, gearing <28%, and average cost of debt ~5.9% (annualized gross interest down $68m since Feb‑2025).

Ryman Healthcare Financial Statement Overview

Summary

Cash flow is the main strength (positive OCF/FCF across years with strong FY26 FCF improvement), and the balance sheet shows moderate leverage and sizable equity. However, the income statement is a major drag: despite steady revenue growth, profitability has deteriorated into large losses in FY25–FY26 with negative operating profit, keeping the overall financial score in the mid-range.

Income Statement

34Negative

Balance Sheet

58Neutral

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue798.49M798.49M713.80M650.53M560.11M503.76M
Gross Profit-17.76M-17.76M713.80M-1.35M-19.77M1.82M
EBITDA50.49M24.79M-27.16M-48.55M264.80M788.44M
Net Income-171.34M-171.34M-436.83M4.78M257.84M692.87M
Balance Sheet
Total Assets12.27B12.27B12.06B13.08B12.51B10.97B
Cash, Cash Equivalents and Short-Term Investments9.70M9.70M17.66M41.81M27.88M28.31M
Total Debt1.59B1.59B1.70B2.57B2.34B2.59B
Total Liabilities8.19B8.19B7.80B8.67B7.85B7.53B
Stockholders Equity4.08B4.08B4.26B4.42B4.66B3.43B
Cash Flow
Free Cash Flow272.38M272.38M302.89M486.28M218.55M237.34M
Operating Cash Flow319.68M319.68M410.25M658.48M542.76M535.97M
Investing Cash Flow-133.32M-133.32M-525.58M-842.05M-1.04B-787.31M
Financing Cash Flow-194.50M-194.50M91.18M197.50M388.60M209.47M

Ryman Healthcare Technical Analysis

Technical Analysis SentimentPositive
Last Price1.88

Price Trends

50DMA1.86Positive
100DMA2.00Negative
200DMA2.13Negative

Market Momentum

MACD0.01Negative
RSI54.78Neutral
STOCH50.51Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:RYM, the sentiment is Positive. The current price of 1.88 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.86, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 50.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:RYM.

Ryman Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:RYM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:SUMNZ:SUM66NeutralNZD 1.46B4.628.89%2.86%14.09%-18.30%
NZ:PHLNZ:PHL63NeutralNZD 33.62M0.03――15.19%1154.17%
NZ:TAHNZ:TAH58NeutralNZD 37.83M11.70―4.21%21.56%18.96%
NZ:RADNZ:RAD56NeutralNZD 113.39M10.18―6.03%9.76%-1.75%
NZ:RYMNZ:RYM56NeutralNZD 1.91B-11.19-4.17%―11.86%72.99%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:OCANZ:OCA50NeutralNZD 449.02M-64.52-0.57%―1.25%-117.68%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%NZ:RYMNZ:OCANZ:SUMNZ:PHLNZ:TAHNZ:RADDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:RYM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:RYMRyman Healthcare 1.88-0.99-34.49%
NZ:OCAOceania Healthcare Ltd.0.62-0.20-24.39%
NZ:SUMSummerset Group Holdings Limited5.95-6.38-51.75%
NZ:PHLPromisia Healthcare Limited0.620.0611.71%
NZ:TAHThird Age Health Services Limited3.80-1.61-29.77%
NZ:RADRadius Residential Care Ltd0.400.024.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026